- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07852156
Cooling During Inpatient Rehabilitation in Persons With MS (CoolEx)
Optimizing Inpatient Rehabilitation - Investigating the Effects of Cooling During Intensive Active Training Sessions on Fatigue in Persons With Multiple Sclerosis
The goal of this clinical trial is to shed light on the use of cooling during intensive active training sessions during a three-week multidisciplinary inpatient rehabilitation stay in persons with Multiple Sclerosis. The objectives of this study are:
- to investigate the effects of one week of using a cooling vest during intensive active training sessions compared with one week of not using a cooling vest during inpatient rehabilitation on the state fatigue in persons with Multiple Sclerosis.
- to investigate the effects of one week of using a cooling vest during intensive active training sessions compared with one week of not using a cooling vest during inpatient rehabilitation on the walking capacity, functional lower limb muscle strength, balance and cognition in persons with Multiple Sclerosis.
- to investigate the effects of the three-week inpatient rehabilitation on the cardiorespiratory fitness, muscle strength and trait fatigue in persons with Multiple Sclerosis.
Researchers will compare the effects of one week of using a cooling vest during intensive active training sessions with one week of not using a cooling vest during intensive active training sessions during three weeks of inpatient rehabilitation.
Participants will
- Wear a cooling vest during intensive active training sessions for one week
- Attend the assessment appointments during study participation
- Keep a diary recording their use of a cooling vest during intensive active training sessions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study has a prospective randomized controlled crossover trial design. During the inpatient stay in the rehabilitation clinic Valens, included participants will be randomized into the following two groups: persons with Multiple Sclerosis will either perform 1) first one week of cooling during intensive active training sessions followed by one week of no cooling during intensive active training sessions, or 2) first one week of no cooling during intensive active training sessions followed by one week of cooling during intensive active training sessions. There is a three-day washout period between the two periods/weeks.
This design was chosen to allow all participants to receive the intervention (i.e. the cooling vest during intensive active training sessions), and that each participant is his/her own control to minimize inter-individual variability.
The investigators hypothesize that one week of cooling during intensive active training sessions prevents an exercise-induced increase in state fatigue, compared to one week without cooling during the same intensive active training sessions, during the three-week inpatient rehabilitation stay in pwMS.
Experimental period:
The experimental period consists of one week of wearing a cooling vest during intensive active training sessions during the inpatient rehabilitation stay. Participants will wear a cooling vest (Inuteq PCM CoolOver 6.5C) on their torso, that, according to the manufacturer's specifications, offers constant cooling for up to 1.5 hours at 6.5 degrees Celsius. Participants are instructed to wear at least a (cotton) shirt under the cooling vest. The following rehabilitation prescriptions are defined as intensive active training sessions: endurance training (ergometer groups), resistance training (machine and bodyweight training), gait training (treadmill training, balance training), and physiotherapy (flexibility, mobility, strength, endurance, balance, walking). In addition, the participants receive their usual multidisciplinary inpatient rehabilitation program.
Control period:
The control period consists of the multidisciplinary inpatient rehabilitation program without cooling during intensive active training sessions.
Multidisciplinary inpatient rehabilitation:
The multidisciplinary inpatient rehabilitation program is tailored to the patients' individual needs and includes physiotherapy (flexibility, mobility, strength, endurance, balance, walking), occupational therapy (ability and adaptation training) and, occasionally, speech therapy, neuropsychological training and/or counselling by a physician or social worker.
There are six measurement timepoints in this study:
- T-1: endpoint assessment at baseline (pre-intervention/control (clinic entry))
- T0: baseline endpoint assessment 1st week of intervention/control
- T1: endpoint assessment after week 1 of intervention/control
- T2: baseline endpoint assessment 2nd week of intervention/control
- T3: endpoint assessment after week 2 of intervention/control
- T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
State fatigue (VAS score), walking capacity, functional lower extremity muscle strength, balance, and cognition will be measured at T0, T1, T2, and T3 to investigate the effect of cooling vs. no cooling.
Additionally, cardiorespiratory fitness and muscle strength will be measured at T-1 and at T4 i) to determine the training intensity, and ii) to investigate the effect of the inpatient stay on cardiorespiratory fitness and muscle strength. Trait fatigue will additionally be measured with the Fatigue Scale for Motor and Cognitive Functions (FSMC) questionnaire at T-1 and at T4, because i) the FSMC total score is used as an inclusion criterion and as a stratification factor, and ii) to investigate the effect of the inpatient stay on trait fatigue.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nadine Patt, M.Sc.
- Phone Number: +41 58 511 13 83
- Email: nadine.patt@kliniken-valens.ch
Study Contact Backup
- Name: Jens Bansi, Dr.
- Phone Number: +41 58 511 13 02
- Email: jens.bansi@kliniken-valens.ch
Study Locations
-
-
Canton of St. Gallen
-
Valens, Canton of St. Gallen, Switzerland, 7317
- Recruiting
- Rehabilitation clinic Valens
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- FSMC total score ≥ 43;
- Adult age (≥ 18 years);
- A definite MS diagnosis according to the 2024 revised McDonald criteria with relapsing-remitting, primary or secondary progressive phenotypes;
- Disease severity according to Expanded disability status scale (EDSS) score 3.0-6.0;
- Subjective perceived heat sensitivity (Yes).
Exclusion Criteria:
- Inability to follow the study procedures (i.e. participant not fluent in oral and written German language);
- Cognitive impairment (Montreal Cognitive Assessment, MoCA score < 26);
- Severe concomitant disease states (i.e. orthopaedic, cardiovascular, metabolic, psychiatric (e.g., substance abuse), other neurological disease states, other serious medical conditions) impairing the ability to participate;
- Participation in another study;
- Pregnant or lactating women;
- Intention to become pregnant during this study;
- Suspected non-compliance;
- Previous enrolment into this study;
- Sudden severe disease progression or falling sick (e.g. bacterial or viral infections) during the study;
- Subjective perceived cold sensitivity (Yes).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
The experimental period consists of one week of wearing a cooling vest during intensive active training sessions. The following rehabilitation prescriptions are defined as intensive active training sessions: endurance training (ergometer groups), resistance training (machine and bodyweight training), gait training (treadmill training), and physiotherapy (flexibility, mobility, strength, endurance, balance, walking). According to the manufacturer's specifications the cooling vest (Inuteq PCM CoolOver 6.5C) offers constant cooling for up to 1.5 hours at 6.5 degrees Celsius. In addition, the participants receive their usual multidisciplinary inpatient rehabilitation program. |
The intervention period consists of one week of wearing a cooling vest during intensive active training sessions. The following rehabilitation prescriptions are defined as intensive active training sessions: endurance training (ergometer groups), resistance training (machine and bodyweight training), gait training (treadmill training), and physiotherapy (flexibility, mobility, strength, endurance, balance, walking). According to the manufacturer's specifications the cooling vest (Inuteq PCM CoolOver 6.5C) offers constant cooling for up to 1.5 hours at 6.5 degrees Celsius. In addition, the participants receive their usual multidisciplinary inpatient rehabilitation program. |
|
Other: Control
The control period consists of the usual multidisciplinary inpatient rehabilitation program without cooling for one week. |
The control period consists of one week of the usual multidisciplinary inpatient rehabilitation program without cooling. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
State Fatigue
Time Frame: T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
State fatigue is measured using a visual analogue scale (VAS) score. The VAS comprises a 10-cm line ranging from "not fatigued at all" on the left end to "the most fatigue imaginable" on the right end. The respondent is asked to place a tick mark on the line to indicate the level of fatigue at that instant in time. The score, which corresponds to the distance from the left end of the scale to the tick mark, indicates the state level of fatigue. |
T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Walking capacity
Time Frame: T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
The Six-Minute Walk Test (6-MWT) is used to determine the total distance in meters covered within six minutes when walking back and forth on a 20-metres hallway, as a measure of endurance walking capacity. Participants are asked to walk back and forth at maximal walking speed for the duration of six minutes. The instruction is standardized as "to walk at fastest speed, and to cover as much distance as possible". Participants are allowed to use a walking aid, if necessary to ensure safe ambulation. |
T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
|
Functional lower extremity muscle strength
Time Frame: T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
The five-time sit to stand (5STS) test measures the time needed for a person to stand up from a chair and sit back down five times as fast as possible. |
T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
|
Balance
Time Frame: T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
The Mini-Balance Evaluation Systems Test (Mini-BESTest) measures the balance capacity of an individual and differentiates between four areas of balance: anticipatory, reactive postural control, sensory orientation and dynamical walking capacities. There are 14 different tasks. Each task will be scored from 0 to 2 points (0 = severe, 1 = moderate, 2 = normal) by the examiner. A maximal total score of 28 points can be achieved. Higher scores indicate better balance. |
T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
|
Cognition
Time Frame: T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
Cognition is tested with the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), composed of the Symbol Digit Modalities Test (SDMT), the Verbal Learning and Memory Test (VLMT), and the Brief Visuospatial Memory Test (BVMT-R). The SDMT assesses processing speed. The test consists of single digits paired with abstract symbols. Rows of the nine symbols are arranged pseudo-randomly. The patient must say the number that corresponds with each symbol within 90 seconds. The VLMT assesses verbal memory. The VLMT comprises a 15-item word list. The list is read aloud five times in the same order to the patient. Patients are required to recall as many items as possible, in any order, after each reading of the list. The BVMT-R assesses visual memory. Participants inspect a 2 × 3 stimulus array of abstract geometric figures. There are three learning trials of 10s. The array is removed, and the participant is required to draw the array from memory. |
T0: baseline endpoint assessment 1st week of intervention/control T1: endpoint assessment after week 1 of intervention/control T2: baseline endpoint assessment 2nd week of intervention/control T3: endpoint assessment after week 2 of intervention/control
|
|
Trait fatigue
Time Frame: T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
Trait fatigue is assessed with the Fatigue Scale for Motor and Cognitive functions (FSMC), that allows separate rating of motor and cognitive fatigue, based on a 5-point Likert scale (range 1-5). Scores range from 20-100 for FSMC total score, and from 10-50 for each subscale (i.e. motor and cognitive). Higher scores indicate a higher level of fatigue. The instrument has defined cut-off scores to classify mildly, moderately, and severely fatigued patients. Cut-off for mild fatigue is set for the total score at 43 and for the motor and cognitive sub-scores at 22. |
T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
|
Muscle strength - upper extremity (row machine)
Time Frame: T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
Muscle strength will be assessed using a five-repetition maximum (5RM) test. The test will be carried out on the seated row machine and will be measured in kilogram (kg). Firstly, the participants should warm up by completing several submaximal repetitions. Then, the 5RM will be determined within four trials with rest periods of 3 min between trials. An initial weight that is within the subject's perceived capacity (~ 50-70% of capacity) will be chosen. Thereafter, the resistance will be progressively increased by 2.5-20 kg until the subject is not able to complete the selected repetition(s). All repetitions should be performed at the same speed of movement and range of motion to ensure consistency between trials. |
T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
|
Muscle strength - lower extremity (leg press)
Time Frame: T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
Muscle strength will be assessed using a five-repetition maximum (5RM) test. The test will be carried out on the leg press and will be measured in kilograms (kg). Firstly, the participants should warm up by completing several submaximal repetitions. Then, the 5RM will be determined within four trials with rest periods of 3 min between trials. An initial weight that is within the subject's perceived capacity (~ 50-70% of capacity) will be chosen. Thereafter, the resistance will be progressively increased by 2.5-20 kg until the subject is not able to complete the selected repetition(s). All repetitions should be performed at the same speed of movement and ran-ge of motion to ensure consistency between trials. |
T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
|
Cardiorespiratory fitness (peak oxygen consumption)
Time Frame: T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
Peak oxygen consumption (VO2peak) in ml/min and in ml/min/kg will be assessed via following progressive cardiopulmonary exercise testing (CPET) on a cycle ergometer (Ergoline 800, Germany): The individual cardiorespiratory fitness level is monitored by direct and continuous measurements (breath by breath) of maximum oxygen consumption (VO2peak) by ergospirometry. The exercise ramp-type protocol consists of (a) a resting state measurement without pedalling while participants are sitting on the bicycle ergometer (2 minutes); (b) subsequent unloaded pedalling (20W) as a warm-up (3 minutes); (c) the testing phase until exhaustion, during which the workload is continuously increased by 5-10W every minute to ensure 8-12 minutes of testing; (d) followed by a cool-down of unloaded pedalling (20W, 3-5 minutes). HR and blood pressure are monitored every 2 minutes and for the last 10 seconds of the test. The rate of perceived exertion (RPE) is assessed via Borg-CR10 scale at phases (c) and (d). |
T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
|
Cardiorespiratory fitness (peak maximum power output)
Time Frame: T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
Peak maximum power output will be assessed in watts via following progressive cardiopulmo-nary exercise testing (CPET) on a cycle ergometer (Ergoline 800, Germany): The individual car-diorespiratory fitness level is monitored by direct and continuous measurements (breath by breath) of maximum oxygen consumption (VO2peak) by ergospirometry. The exercise ramp-type protocol consists of (a) a resting state measurement without pedalling while participants are sitting on the bicycle ergometer (2 minutes); (b) subsequent unloaded pedalling (20W) as a warm-up (3 minutes); (c) the testing phase until exhaustion, during which the workload is con-tinuously increased by 5-10W every minute to ensure 8-12 minutes of testing; (d) followed by a cool-down of unloaded pedalling (20W, 3 - 5 minutes). HR and blood pressure are monitored every 2 minutes and for the last 10 seconds of the test. The rate of perceived exertion (RPE) is assessed via Borg-CR10 scale at phases (c) and (d). |
T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
|
Cardiorespiratory fitness (peak heartrate)
Time Frame: T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
Peak heart rate will be assessed in beats per minutes via following progressive cardiopulmonary exercise testing (CPET) on a cycle ergometer (Ergoline 800, Germany): The individual cardiore-spiratory fitness level is monitored by direct and continuous measurements (breath by breath) of maximum oxygen consumption (VO2peak) by ergospirometry. The exercise ramp-type pro-tocol consists of (a) a resting state measurement without pedalling while participants are sit-ting on the bicycle ergometer (2 minutes); (b) subsequent unloaded pedalling (20W) as a warm-up (3 minutes); (c) the testing phase until exhaustion, during which the workload is continuous-ly increased by 5-10W every minute to ensure 8-12 minutes of testing; (d) followed by a cool-down of unloaded pedalling (20W, 3 - 5 minutes). HR and blood pressure are monitored every 2 minutes and for the last 10 seconds of the test. The rate of perceived exertion (RPE) is asses-sed via Borg-CR10 scale at phases (c) and (d). |
T-1: endpoint assessment at pre-intervention/control (clinic entry) T4: endpoint assessment post-intervention/control (3 weeks after clinic entry)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sample characteristics - demographic data (age)
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
The age of the participants will be assessed in years. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
Sample characteristics - demographic data (sex)
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
The sex of the participants (female / male / diverse) will be recorded for the description of the study sample. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
Sample characteristics - anthropometric data (height)
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
The participants' height will be recorded in meters. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
Sample characteristics - anthropometric data (weight)
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
The weight of the participants will be assessed in kilograms. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
Sample characteristics - anthropometric data (body mass index)
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
To describe the characteristics of the participants, the body mass index (BMI) is calculated by combining weight (in kg) and height (in m) in kg/m². |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
MS-related Data (phenotype)
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
For the description of the study sample, MS phenotype (Relapsing-Remitting MS (RRMS) / Secondary Progressive MS (SPMS) / Primary Progressive MS (PPMS)) will be assessed from medical records. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
MS-related data (Expanded Disability Status Scale )
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
For the description of the study sample, Expanded Disability Status Scale (EDSS) will be assessed from medical records. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
MS-related data (time since diagnosis)
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
For the description of the study sample, time since diagnosis will be assessed from medical records and reported in months. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
MS-related data (disease modifying treatment)
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
For the description of the study sample, disease modifying treatments will be assessed from medical records and will recorded in the form of the drug name and the name of the active ingredient. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
Use of medications
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
Participants' medication use will be assessed based on medical records and is listed by the name of the medication and the active ingredient. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
Comorbid disorders
Time Frame: At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
For the description of the study sample, participants' comorbid disorders will be assessed from medical records and will be listed by the name of the medication and the active ingredient. |
At measurement timepoint T-1 (endpoint assessment at baseline (pre-intervention/control (clinic entry)).
|
|
Documentation of the use of the cooling vest during the cooling period
Time Frame: Every day during the week of cooling
|
The following quantitative parameters will be assessed with the questionnaire/diary: outdoor temperature, therapy during which the cooling vest was worn, time of day and duration for which the cooling vest was worn, reason for non-use, cooling effect, and clothing worn under the cooling vest. |
Every day during the week of cooling
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026-01492
- 2025-25 (Other Grant/Funding Number: Swiss Multiple Sclerosis Society)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.